看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。- ~- L# }9 \1 B! l0 i- N O
; j# s5 |! E9 q) Q
2 s! U4 @9 q% q: v D" H9 J# t7 sCurrently available feasibility data for possible combination strategies. / f0 r4 H; t7 W. v1 X1 P7 d
————————————————————————————————
' Y, y0 T( M4 K) p9 uCombination Feasibility according to preliminary data
* I" c( d1 c4 C. S——————————————————————————————————
/ N9 k, K+ w8 d: I& R2 t/ LBevacizumab + sorafenib Yes, reduced dose
, A. A, b' d( o1 e9 }! S$ F0 \Bevacizumab + sunitinib† No $ |4 b- q: o! x! ]. x+ q. I5 R
Bevacizumab + temsirolimus Yes
1 d7 s7 K f" `+ t* W- Z- LBevacizumab + everolimus Yes 5 b" h5 T9 \# S: ^
Sorafenib + sunitinib ?
7 L; Q7 o; J t* H. ]7 GSorafenib + temsirolimus Yes, reduced dose 7 v* F+ i' G [ l2 W" M8 k
Sorafenib + everolimus Yes, reduced dose 0 S# p' r M- v+ \$ W
Sunitinib + temsirolimus† No : B7 d0 d a- j: k$ r* P+ o/ W
Sunitinib + everolimus ?
8 h$ C! v( P/ p- v( rTemsirolimus + everolimus ?
# y- U7 Z( j! R————————————————————
6 m g3 W# o% e7 M. X/ H†Led to US FDA warning./ D% T% N& |1 s4 P# X& X
?: As yet unattempted combination.
3 ] r9 }3 N1 F& R" r9 q2 R |